July 12, 2021 7:55am
Markets stutter as the cell and gene therapy sector gets a case of risk tremors, cut some positions
Pre-open indications: BUY: BLUE; SELL: CRSP, FATE, GBT; 1 Maintain SELL: BSTG
My version of the morning’s “indications” is about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session
Dow futures are DOWN -0.31% (-107 points), S&P futures are DOWN -0.14% (-6 point) and NASDAQ futures are UP +0.22% (+32 points)
Monday’s a.m.’s futures are fluctuating mostly to the downside open although the Nasdaq is positive
European stocks were trading around the flatline
Asia-Pacific markets were on the rise, with shares in Japan, Korea, Australia and China with gains
Henry’omics:
The three (3) major indexes closed at record highs on Friday after a sell-off Thursday as investors worried about a potential slowdown in U.S. economic growth.
Friday’s evening’s recap: “yet another comeback to our upside delight in a changing July; however, earnings or LPS (loss-per-share) season is just around the corner” … https://www.regmedinvestors.com/articles/11992
- The Nasdaq closed UP +142.13 points (+0.98);
- The IBB closed up +0.20% and XBI closed up +0.48%;
- Sector volume was LOW with 3 of the 27-upside having higher than the 3-month average volume with NADA volume of 0 of 6-downside having higher than the 3-month average volume;
- The CBOE Volatility Index (VVIX: INDEX) was down -2.82 points or -14.84% at 16.18;
- Friday’s percentage (%) of the 27-upside were +0.18% (NTLA) to +9.28% (CLLS) while the 6-downside ranges from -0.33% (CRSP) to -2.78% (VCEL);
Q3/21: 3 positive and 3 negative close
Q2/21:
- June: 15 positive and 8 negative closes
- May: 8 positive, 12 negative closes and 1 holiday
- April: 11 negative and 10 positive closes
Q1/21:
- March: 10 positive, 12 negative and 1 neutral closes
- February: 9 positive, 10 negative closes and 1 holiday
- January: 10 positive, 9 negative closes and 1 holiday
Companies in my headlights – It’s your decision; I provide an idea and context:
The Biostage (BSTG) - Maintaining Sell – Could the share price stay up if it wasn’t “pumped”?
Biostage (BSTG) closed flat at on Friday at $1.50 with 1,060 shares traded after Thursday’s +$0.23 to $1.50 with 210 shares traded, Wednesday’s -$0.23 to $1.27 with 15,903 shares traded, Tuesday’s +$0.15 to $1.50 with 5,702 shares traded and the previous Friday’s -$0.00 with 1,974 shares traded.
Question#1: WHAT role is DST Capital “playing” in these on-going “volume-pumping” pricing “moves” – to exercise the remaining outstanding warrants to add even more unregistered shares to the “outstanding”?
Question#2: WHO and WHAT has facilitated <” made it easy or easier to get where they are”> most of the issues with BSTG?
Question#3: Is protecting the share price the ONLY factor indication of a “inflated” pricing of the private placements that has jeopardized ANY sort of future financing?
MINORITY PUBLIC shareholders are waiting for the specific time, watching and weighing responses to MAINTAIN their RIGHTS.
The morning’s indications:
BUY
bluebird bio (BLUE) closed up +$0.14 to $30.57 and has a positive +$0.33 or +1.08% pre-market indication.
SELL:
CRISPR Therapeutics (CRSP) closed down -$0.48 to $144.33 but, has a negative -$0.80 or -0.55% pre-market indication.
Fate Therapeutics (FATE) closed up +$3.24 to $90.45 but, has a negative -$0.24 or -0.27% pre-market indication.
Global Blood Therapeutics (GBT) closed up +$0.77 to $34.90 but, has a negative -$0.99 or -2.84% pre-market indication.
The BOTTOM LINE: It takes courage to not being discouraged by “our” universe of cell and gene therapy equities or sector …
As my vacation week starts on a very wet note yet, I am still writing.
In my role as a research analyst and journalist is a balancing “act”, WHAT CHANGES; many times, I scratch my head over how to cover volatile cell and gene therapy equities – it’s the INDICATIONS that focus my “leanings”.
I also continue to MAINTAIN, this is a confused sector as sentiment rages and fades, momentum is usurped, fundamentals are being ignored.
My focus has always been “indication and warning analysis” … my advice, trim and skim any new highs if one can!” I also see a number of lows that could be in the “pick-up” stock game.
My motto, never leave an investor uninformed about what I know!
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
